GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Beneish M-Score

TWST (Twist Bioscience) Beneish M-Score : -3.50 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Twist Bioscience's Beneish M-Score or its related term are showing as below:

TWST' s Beneish M-Score Range Over the Past 10 Years
Min: -3.62   Med: -2.37   Max: -0.68
Current: -3.5

During the past 9 years, the highest Beneish M-Score of Twist Bioscience was -0.68. The lowest was -3.62. And the median was -2.37.


Twist Bioscience Beneish M-Score Historical Data

The historical data trend for Twist Bioscience's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Beneish M-Score Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -1.65 -0.68 -2.17 -2.57 -3.50

Twist Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 -2.95 -3.18 -3.52 -3.50

Competitive Comparison of Twist Bioscience's Beneish M-Score

For the Diagnostics & Research subindustry, Twist Bioscience's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Beneish M-Score falls into.



Twist Bioscience Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Twist Bioscience for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6203+0.528 * 0.8592+0.404 * 0.9021+0.892 * 1.2769+0.115 * 0.7726
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9015+4.679 * -0.157982-0.327 * 1.1704
=-3.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $34.9 Mil.
Revenue was 84.71 + 81.464 + 75.302 + 71.498 = $313.0 Mil.
Gross Profit was 38.233 + 35.271 + 30.882 + 28.962 = $133.3 Mil.
Total Current Assets was $346.8 Mil.
Total Assets was $614.3 Mil.
Property, Plant and Equipment(Net PPE) was $161.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $31.4 Mil.
Selling, General, & Admin. Expense(SGA) was $218.4 Mil.
Total Current Liabilities was $71.0 Mil.
Long-Term Debt & Capital Lease Obligation was $70.2 Mil.
Net Income was -34.655 + -85.571 + -45.492 + -43.008 = $-208.7 Mil.
Non Operating Income was -2.299 + -45.051 + -0.199 + -0.031 = $-47.6 Mil.
Cash Flow from Operations was -15.32 + -6.378 + -19.423 + -22.973 = $-64.1 Mil.
Total Receivables was $44.1 Mil.
Revenue was 66.946 + 63.74 + 60.18 + 54.243 = $245.1 Mil.
Gross Profit was 24.522 + 21.895 + 18.511 + 24.801 = $89.7 Mil.
Total Current Assets was $424.3 Mil.
Total Assets was $776.4 Mil.
Property, Plant and Equipment(Net PPE) was $203.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $29.3 Mil.
Selling, General, & Admin. Expense(SGA) was $189.7 Mil.
Total Current Liabilities was $73.3 Mil.
Long-Term Debt & Capital Lease Obligation was $79.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(34.903 / 312.974) / (44.064 / 245.109)
=0.11152 / 0.179773
=0.6203

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(89.729 / 245.109) / (133.348 / 312.974)
=0.366078 / 0.426067
=0.8592

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (346.776 + 161.349) / 614.323) / (1 - (424.256 + 203.361) / 776.403)
=0.17287 / 0.191635
=0.9021

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=312.974 / 245.109
=1.2769

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(29.31 / (29.31 + 203.361)) / (31.432 / (31.432 + 161.349))
=0.125972 / 0.163045
=0.7726

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(218.398 / 312.974) / (189.737 / 245.109)
=0.697815 / 0.774092
=0.9015

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((70.221 + 71.006) / 614.323) / ((79.173 + 73.323) / 776.403)
=0.22989 / 0.196413
=1.1704

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-208.726 - -47.58 - -64.094) / 614.323
=-0.157982

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Twist Bioscience has a M-score of -3.50 suggests that the company is unlikely to be a manipulator.


Twist Bioscience Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Twist Bioscience Business Description

Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Executives
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Dennis Cho officer: See Remarks C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Patrick John Finn officer: VP of Sales and Marketing C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Emily M. Leproust director, officer: President & CEO C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green officer: VP of Human Resources C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Robert Chess director
William Banyai director, officer: Chief Operating Officer C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Melissa A. Starovasnik director C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen director 5555 NE MOORE CT., HILLSBORO OR 97124
James M Thorburn officer: Chief Financial Officer C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Patrick Weiss officer: VP of Operations C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton officer: Chief Accounting Officer 1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels officer: Chief Compliance Officer & GC C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158